Welcome to our dedicated page for Viking Therapeutics SEC filings (Ticker: VKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viking Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, and clinical-development disclosures for VK2735, including subcutaneous and oral obesity programs, trial results, and related regulatory communications.
The company's proxy materials disclose board and shareholder-voting matters, executive compensation, equity awards, and pay-versus-performance information. Viking's SEC record also covers Regulation FD communications, clinical-development updates, cash resources, and governance matters tied to a development-stage biotechnology issuer.
Viking Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of the 115,893,943 common shares outstanding as of March 20, 2026, 80,089,532 shares were represented, about 69.1% of shares entitled to vote, establishing a quorum.
Stockholders elected Class II directors J. Matthew Singleton and S. Kathryn Rouan, Ph.D., to serve until the 2029 annual meeting or until their successors are elected and qualified. They also ratified the selection of CBIZ CPAs P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026.
On an advisory basis, stockholders approved the compensation of the company’s named executive officers as disclosed in the proxy statement. These outcomes confirm continuity in Viking’s board composition, auditor relationship, and executive pay program.
Vanguard Capital Management reported beneficial ownership of 5,877,263 shares of Viking Therapeutics Inc. common stock (5.08% of the class) as of 03/31/2026. The filing shows sole voting power of 864,761 shares and sole dispositive power over 5,877,263 shares, and states these holdings include securities held for Vanguard funds and managed accounts.
Viking Therapeutics reported a much larger quarterly loss as it ramped up late‑stage obesity trials and faced a new licensing dispute. For the three months ended March 31, 2026, the company recorded a net loss of $158.3 million, compared with $45.6 million a year earlier, driven mainly by higher research and development spending.
R&D expenses rose to $150.2 million as Viking advanced its Phase 3 VANQUISH-1 and VANQUISH-2 studies of obesity drug VK2735 and continued work on other metabolic programs. The company ended the quarter with $118.1 million in cash and $484.8 million in short‑term investments, supporting an equity base of $501.9 million. Viking also highlighted a dispute with Ligand Pharmaceuticals, which has notified Viking that it is purporting to terminate the license for the TR‑Beta program, including VK2809; Viking states it believes Ligand has no such right and plans to vigorously defend its position.
Viking Therapeutics reported a larger first quarter 2026 loss as it ramps investment in its obesity pipeline. The company posted a net loss of $158.3 million, or $1.37 per share, compared with a net loss of $45.6 million, or $0.41 per share, a year earlier. Research and development expenses rose to $150.2 million from $41.4 million, while general and administrative costs were roughly flat at $14.0 million.
Viking ended March 31, 2026 with $603 million in cash, cash equivalents and short-term investments, down from $706 million at year-end 2025, supporting continued clinical work. Its Phase 3 VANQUISH trials of subcutaneous VK2735 for obesity are fully enrolled, with more than 4,500 patients in VANQUISH-1 and approximately 1,000 in VANQUISH-2. A Phase 3 trial of oral VK2735 in obesity is planned to start in the fourth quarter of 2026, a maintenance dosing study is ongoing with data expected in the third quarter of 2026, and an IND has been filed for amylin agonist VK3019, with a Phase 1 trial targeted for the second quarter of 2026.
Viking Therapeutics is asking stockholders to vote at its virtual 2026 Annual Meeting on May 19, 2026 at 8:00 a.m. Pacific Time. Holders of 115,893,943 common shares as of March 20, 2026 can vote on electing two Class II directors, ratifying CBIZ CPAs P.C. as auditor for 2026, and approving executive compensation on an advisory basis. The meeting will be held via live webcast and requires a quorum of at least 57,946,972 shares. The proxy statement also outlines board structure, committee responsibilities, director independence and an executive pay program that emphasizes performance-based equity and annual incentives.
The Vanguard Group filed an Amendment No. 3 to Schedule 13G reporting that it beneficially owns 0 shares of Viking Therapeutics Inc common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries or business divisions to report beneficial ownership separately.
The amendment is signed by Ashley Grim, Head of Global Fund Administration, and lists Vanguard's principal business address in Malvern, Pennsylvania.
Viking Therapeutics, Inc. reported that Chief Commercial Officer Neil William Aubuchon purchased common stock in the company. On this transaction date, he made an open-market purchase of 4,475 shares of common stock at $33.50 per share. Following this trade, he directly holds 4,475 shares of Viking Therapeutics common stock.
Viking Therapeutics outlines a broad late-stage pipeline for metabolic and endocrine diseases in its annual report. Lead obesity candidate VK2735, a dual GLP-1/GIP agonist, has moved into Phase 3 VANQUISH studies after Phase 2 data showed up to 14.7% mean weight loss over 13 weeks and up to 88% of patients achieving at least 10% weight reduction.
The oral tablet form of VK2735 delivered up to 12.2% weight loss versus 1.3% with placebo over 13 weeks, supporting planned Phase 3 oral studies. NASH/MASH candidate VK2809 produced robust 52‑week histology results, with NASH resolution in up to 75% of patients and ≥1‑stage fibrosis improvement in up to 57%, both outperforming placebo.
Viking also reports positive early data in rare disease program VK0214 for X‑ALD and muscle‑building agent VK5211, while securing large-scale VK2735 manufacturing through multi‑year CordenPharma agreements. As context, non‑affiliate equity was valued at $2,976,737,289 as of June 30, 2025, with 115,554,295 shares outstanding as of January 31, 2026.
Viking Therapeutics reported a much larger net loss for 2025 as it accelerated investment in its obesity pipeline, led by dual GLP‑1/GIP agonist VK2735. For 2025, the company recorded a net loss of $358.5 million, or $3.19 per share, versus a loss of $110.0 million, or $1.01 per share, in 2024. Research and development spending rose to $345.0 million from $101.6 million, reflecting extensive Phase 3 work on subcutaneous VK2735, positive Phase 2 oral VK2735 data, and broader pipeline progress. General and administrative costs were roughly flat at $48.4 million. As of December 31, 2025, Viking held $706 million in cash, cash equivalents and short‑term investments, which the company believes supports key upcoming milestones. Clinical highlights include ongoing Phase 3 VANQUISH trials for injectable VK2735 in obesity, plans to start Phase 3 for oral VK2735 in 3Q26, a fully enrolled VK2735 maintenance dosing study with data expected in 3Q26, and plans to file an IND for a novel amylin agonist in 1Q26.